Castle Biosciences Stock Price, News & Analysis

Castle Biosciences (CSTL) has entered a strategic collaboration and license agreement with SciBase to develop diagnostic tests for dermatologic diseases using SciBase's Electrical Impedance Spectroscopy technology. The initial focus is on developing a test to predict flares in atopic dermatitis (AD) patients, targeting a potential U.S. market of 24 million patients. The collaboration divides territories with SciBase covering EU, Switzerland, UAE, Japan, and South Korea, while Castle operates in North America. The agreement includes revenue sharing with SciBase receiving single-digit royalties on Castle's gross margin, a low double-digit markup on product sales, and a $5 million milestone payment when Castle's annual sales reach $50 million. Development costs will be shared, with SciBase deferring initial clinical development costs for AD flare prediction, to be reimbursed from future royalties and milestone payments.

Castle Biosciences (CSTL) announced that CEO Derek Maetzold will participate in a panel discussion at the 2025 BIO International Convention in Boston from June 16-19. The panel, titled 'Advancing Innovative Risk-Stratification Tests That Impact Treatment Pathway Decisions: Challenges in Overcoming Barriers to Entry,' will focus on challenges faced by precision medicine companies in commercializing diagnostic tests. The session will take place on June 17, 2025, from 11 a.m.-12 p.m. Eastern Time in Room 251. The panel will be moderated by Michael Ryan from McDermott Will & Emery and include industry experts Mara Aspinall from Illumina Ventures and Gillian Hooker from Concert. Castle Biosciences will also be represented at the City of Phoenix Pavilion (1639) and Texas Pavilion (2665).

Castle Biosciences (CSTL) will present new research at ASCO 2025 showcasing the effectiveness of their DecisionDx-Melanoma test in improving melanoma patient care. The study, involving over 13,500 patients, demonstrates that the test was associated with a 32% reduction in mortality risk compared to untested patients. The 31-gene expression profile test significantly stratified mortality risk within AJCC sub-stages, with Class 2B patients showing a hazard ratio of 4.59 and Class 1B/2A patients showing 3.42 (p<0.001). Additionally, Castle will present findings on a new 16-protein test for uveal melanoma, showing 91% sensitivity and 92% negative predictive value in distinguishing between low and high-risk uveal melanoma lesions through liquid biopsy.

Castle Biosciences (NASDAQ: CSTL), a healthcare company focused on innovative diagnostic testing, has announced its participation in the upcoming 2025 Jefferies Global Healthcare Conference. The company's executive management will deliver a corporate presentation on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. Investors and interested parties can access the live audio webcast through Castle Biosciences' investor relations website, with a replay available after the presentation.

Castle Biosciences (NASDAQ: CSTL) presented new data validating their DecisionDx-UM test and PRAME biomarker for uveal melanoma (UM) at the ARVO 2025 Annual Meeting. The study analyzed a real-world cohort of 1,297 patients with UM, validating findings from the COOG2.1 study.

The research confirms that combining PRAME gene expression information with DecisionDx-UM test results can better predict metastatic risk in UM patients. The study utilized data from the National Cancer Institute's SEER Program, demonstrating that co-reporting DecisionDx-UM class and PRAME status provides enhanced insights into metastasis likelihood, enabling more personalized treatment strategies for this rare but aggressive eye cancer.

Castle Biosciences (NASDAQ: CSTL) is commemorating Skin Cancer Awareness Month in May 2025 through various initiatives and partnerships. The company is sponsoring IMPACT Melanoma's virtual patient symposium "Melanoma Diagnosis: A Toolkit to Support the Journey" on May 21, featuring Dr. Aaron Farberg. Castle is also highlighting melanoma survivor Leah Adams' story, who benefited from their DecisionDx-Melanoma test for recurrence risk assessment.

The company continues partnerships with IMPACT Melanoma, AIM at Melanoma, and Melanoma Research Foundation, participating in advocacy walks nationwide. Additionally, Castle will be featured in USA TODAY's 2025 Skin Health Campaign, with an article titled "Transforming Skin Cancer and Melanoma Outcomes" appearing in the May 30 edition.

Castle Biosciences (CSTL) reported strong Q1 2025 results with revenue increasing 21% to $88 million compared to Q1 2024. The company delivered 24,402 total test reports, up 17% year-over-year. Core revenue drivers showed significant growth, with DecisionDx-Melanoma surpassing 200,000 test orders milestone. The company raised its 2025 revenue guidance to $287-297 million from $280-295 million. Notable metrics include DecisionDx-Melanoma (8,621 tests), DecisionDx-SCC (4,375 tests), and TissueCypher (7,432 tests). However, the company reported a net loss of $25.8 million and will discontinue its IDgenetix test offering in May 2025. Cash position remains strong at $275.2 million as of March 31, 2025.

Castle Biosciences (CSTL) has announced a definitive agreement to acquire Previse, a gastrointestinal health company specializing in chronic acid reflux related diseases and esophageal cancer. The acquisition aims to expand Castle's GI testing portfolio beyond their existing TissueCypher Barrett's Esophagus test. Previse's key assets include methylation technology developed at Johns Hopkins University School of Medicine and additional pipeline technologies. The deal, with undisclosed terms, is expected to close within weeks, subject to customary conditions. The acquisition aligns with Castle's strategy to enhance their gastroenterology franchise and address unmet needs in GI testing, including potential upstream opportunities.

Castle Biosciences (CSTL) will present new data on its TissueCypher Barrett's Esophagus test at the Digestive Disease Week (DDW 2025) Annual Meeting in San Diego from May 3-6. The company will showcase two key posters demonstrating TissueCypher's ability to identify patients with Barrett's esophagus who are at higher risk for developing esophageal cancer. A product theater featuring an expert physician panel will discuss clinical practice models for preventing progression from Barrett's to EAC. The presentations include research on the test's effectiveness in detecting missed neoplasia and providing risk stratification for Barrett's esophagus patients. Castle Biosciences will also participate in educational sessions in collaboration with GI experts and the American Society for Gastrointestinal Endoscopy (ASGE).